Naphthoquinone Derivatives Exert Their Antitrypanosomal Activity via a Multi-Target Mechanism

Background and Methodology Recently, we reported on a new class of naphthoquinone derivatives showing a promising anti-trypanosomatid profile in cell-based experiments. The lead of this series (B6, 2-phenoxy-1,4-naphthoquinone) showed an ED50 of 80 nM against Trypanosoma brucei rhodesiense, and a selectivity index of 74 with respect to mammalian cells. A multitarget profile for this compound is easily conceivable, because quinones, as natural products, serve plants as potent defense chemicals with an intrinsic multifunctional mechanism of action. To disclose such a multitarget profile of B6, we exploited a chemical proteomics approach. Principal Findings A functionalized congener of B6 was immobilized on a solid matrix and used to isolate target proteins from Trypanosoma brucei lysates. Mass analysis delivered two enzymes, i.e. glycosomal glycerol kinase and glycosomal glyceraldehyde-3-phosphate dehydrogenase, as potential molecular targets for B6. Both enzymes were recombinantly expressed and purified, and used for chemical validation. Indeed, B6 was able to inhibit both enzymes with IC50 values in the micromolar range. The multifunctional profile was further characterized in experiments using permeabilized Trypanosoma brucei cells and mitochondrial cell fractions. It turned out that B6 was also able to generate oxygen radicals, a mechanism that may additionally contribute to its observed potent trypanocidal activity. Conclusions and Significance Overall, B6 showed a multitarget mechanism of action, which provides a molecular explanation of its promising anti-trypanosomatid activity. Furthermore, the forward chemical genetics approach here applied may be viable in the molecular characterization of novel multitarget ligands.

[1]  C. Clayton,et al.  Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei. , 1997, Molecular and biochemical parasitology.

[2]  Jan-Hendrik S. Hofmeyr,et al.  Modelling cellular systems with PySCeS , 2005, Bioinform..

[3]  L. Scapozza,et al.  Adenosine Kinase of T. b. rhodesiense Identified as the Putative Target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine Using Chemical Proteomics , 2009, PLoS neglected tropical diseases.

[4]  D. Durrheim,et al.  Current Concepts Control of Neglected Tropical Diseases , 2007 .

[5]  Robert A. Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery , 2013 .

[6]  J. Garbarino,et al.  Effects and mode of action of 1,4-naphthoquinones isolated from Calceolaria sessilis on tumoral cells and Trypanosoma parasites. , 1995, Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology.

[7]  A. Cavalli,et al.  Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. , 2010, FEMS immunology and medical microbiology.

[8]  G. Folkers,et al.  A spectrophotometric assay for quantitative determination of kcat of herpes simplex virus type 1 thymidine kinase substrates. , 2001, Analytical biochemistry.

[9]  R. Kaminsky,et al.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.

[10]  Adam R Renslo,et al.  Drug discovery and development for neglected parasitic diseases , 2006, Nature chemical biology.

[11]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[12]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[13]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[14]  V. Hannaert,et al.  Glycosomal glyceraldehyde-3-phosphate dehydrogenase of Trypanosoma brucei and Trypanosoma cruzi: expression in Escherichia coli, purification, and characterization of the enzymes. , 1995, Protein expression and purification.

[15]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[16]  A. Chan,et al.  The molecular mechanisms involved in the cytotoxicity of alkannin derivatives. , 2005, European journal of medicinal chemistry.

[17]  F. Opperdoes,et al.  Glycerol kinase of Trypanosoma brucei. Cloning, molecular characterization and mutagenesis. , 2000, European journal of biochemistry.

[18]  Barbara M. Bakker,et al.  Experimental and in Silico Analyses of Glycolytic Flux Control in Bloodstream Form Trypanosoma brucei* , 2005, Journal of Biological Chemistry.

[19]  Gavin Yamey,et al.  The world's most neglected diseases , 2002, BMJ : British Medical Journal.

[20]  B. Nare,et al.  2,4-Diaminopyrimidines as Potent Inhibitors of Trypanosoma brucei and Identification of Molecular Targets by a Chemical Proteomics Approach , 2011, PLoS neglected tropical diseases.

[21]  '. FREDM.D.VELLIEUXa,et al.  Structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei determined from Laue data. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Fèvre,et al.  The Burden of Human African Trypanosomiasis , 2008, PLoS neglected tropical diseases.

[23]  R. Tapia,et al.  Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease. , 2011, Current medicinal chemistry.

[24]  Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases. , 2011, Current topics in medicinal chemistry.

[25]  Michael P Barrett,et al.  The trypanosomiases , 2003, The Lancet.

[26]  G. Lenaz,et al.  Mitochondrial production of reactive oxygen species: Role of Complex I and quinone analogues , 2008, BioFactors.

[27]  Ian H Gilbert,et al.  Finding new hits in neglected disease projects: target or phenotypic based screening? , 2011, Current topics in medicinal chemistry.

[28]  R. Tarleton,et al.  Oral Exposure to Trypanosoma cruzi Elicits a Systemic CD8+ T Cell Response and Protection against Heterotopic Challenge , 2011, Infection and Immunity.

[29]  S. Croft,et al.  Natural products as antiparasitic drugs , 2003, Parasitology Research.

[30]  E. Tisdale,et al.  Glyceraldehyde-3-phosphate Dehydrogenase Interacts with Rab2 and Plays an Essential Role in Endoplasmic Reticulum to Golgi Transport Exclusive of Its Glycolytic Activity* , 2004, Journal of Biological Chemistry.

[31]  Shin-ichi Sato,et al.  Biochemical target isolation for novices: affinity-based strategies. , 2010, Chemistry & biology.

[32]  Z. Lun,et al.  Drug sensitivity of Chinese Trypanosoma evansi and Trypanosoma equiperdum isolates. , 1994, Veterinary parasitology.

[33]  Barbara M. Bakker,et al.  A domino effect in drug action: from metabolic assault towards parasite differentiation , 2011, Molecular microbiology.

[34]  C L Verlinde,et al.  Glycolysis as a target for the design of new anti-trypanosome drugs. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[35]  Salah Ghabri,et al.  Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.

[36]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[37]  P. Michels,et al.  Glucose-6-phosphate dehydrogenase is the target for the trypanocidal action of human steroids. , 2011, Molecular and biochemical parasitology.

[38]  Robert B. Raffa,et al.  DRUG-RECEPTOR THERMODYNAMICS : introduction and applications , 2001 .

[39]  A. Cavalli,et al.  Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity. , 2008, Bioorganic & medicinal chemistry letters.

[40]  J. Turrens Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. , 2004, Molecular aspects of medicine.

[41]  R. Brun,et al.  Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Short communication. , 1979, Acta tropica.

[42]  T. Terada,et al.  Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. , 2004, Bioorganic & medicinal chemistry.

[43]  P. Michels,et al.  Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. , 2009, Bioorganic & medicinal chemistry.

[44]  R. Nilakantan,et al.  2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. , 2005, Journal of medicinal chemistry.

[45]  Maria Laura Bolognesi,et al.  Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. , 2009, Journal of medicinal chemistry.

[46]  M. Wink Ecological Roles of Alkaloids , 2007 .

[47]  Michael P Barrett,et al.  Proline Metabolism in Procyclic Trypanosoma brucei Is Down-regulated in the Presence of Glucose* , 2005, Journal of Biological Chemistry.

[48]  R. Pink,et al.  Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.

[49]  R. Perozzo,et al.  Turkish freshwater and marine macrophyte extracts show in vitro antiprotozoal activity and inhibit FabI, a key enzyme of Plasmodium falciparum fatty acid biosynthesis. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[50]  Robert A. Copeland,et al.  Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .

[51]  R. Docampo,et al.  Superoxide anion production and trypanocidal action of naphthoquinones on Trypanosoma cruzi. , 1978, Comparative biochemistry and physiology. C: Comparative pharmacology.

[52]  T. Halgren,et al.  Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .

[53]  R Abagyan,et al.  Flexible protein–ligand docking by global energy optimization in internal coordinates , 1997, Proteins.

[54]  Ram Samudrala,et al.  Identification of potential multitarget antimalarial drugs. , 2005, JAMA.

[55]  R. Olsen,et al.  Identification of Direct Protein Targets of Small Molecules , 2010, ACS chemical biology.

[56]  H. Scheraga,et al.  Energy parameters in polypeptides. 10. Improved geometrical parameters and nonbonded interactions for use in the ECEPP/3 algorithm, with application to proline-containing peptides , 1994 .

[57]  Renata L. S. Goncalves,et al.  The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction. , 2009, Free radical biology & medicine.

[58]  Solange Lisboa de Castro,et al.  The Trypanocidal Activity of Naphthoquinones: A Review , 2009, Molecules.

[59]  Matthew Bogyo,et al.  Chemical proteomics and its application to drug discovery. , 2003, Current opinion in biotechnology.

[60]  Simon Croft,et al.  Kinetoplastids: related protozoan pathogens, different diseases. , 2008, The Journal of clinical investigation.

[61]  L. Meijer,et al.  Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography , 2007, Biotechnology journal.

[62]  C. de Duve Principles of tissue fractionation. , 1964, Journal of theoretical biology.

[63]  M. E. González-Rosende,et al.  The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives. , 2012, Current medicinal chemistry.

[64]  G M Cohen,et al.  Quinone chemistry and toxicity. , 1992, Toxicology and applied pharmacology.